DFX Intelligence
Private Equity Intelligence
The names on this page are hidden. Create a free account to reveal 5 records a month, or get Private Equity Intelligence at $249 a month for every name. Every figure, date and source on this page is public either way.
Firms / 4••• P••••••• L••
4••• P••••••• L••
Venture firm with private equity activity · probableLower middle marketLondon4•••••••••.comSEC registered investment adviser
Classification
- Class
- Venture firm with private equity activityprobable, confidence 80%
- Basis
- own website statement
- Size band
- Lower middle marketdefined by: proxy: $0.16bn Private Equity Fund GAV on the Form ADV filed 2024-10-11
Classification history (2)
- Sep 18, 2026Venture firm with private equity activity (probable, 80%, cls-pe-2)own website statement“4BIO Capital is a London-based venture capital firm focused solely on the advanced therapies sector.”4•••••••••.com
- Sep 13, 2026Buyout firm (confirmed, 85%, cls-pe-1)R6: 2 of 4 distinct vehicles are sworn P•••••• Equity Funds; 2 reported gross assets on a filing in 2022 or later
Regulatory footprint (Form ADV)
- Adviser type
- registered investment adviser
- Form ADV filings
- Apr 29, 2021 to Oct 11, 2024
- RAUM
- $167Mregulatory assets under management of the adviser; not dry powder, not a fund size
- PE funds, latest filing
- 2
- PE fund GAV, latest filing
- $159Mreported gross assets (Form ADV), not fund size
- All private fund GAV
- $167Mevery private fund type, latest filing
- 2024 PE fund GAV
- $159Msum over funds typed Private Equity Fund with a 2024 or later as-of date
- PE share of funds, lifetime
- 50%
- Fund type mix
- filed 2024-10-11, latest gav Liquidity Fund $8.5M, Private Equity Fund $159M, latest counts Liquidity Fund 2, Private Equity Fund 2, lifetime distinct Liquidity Fund 2, Private Equity Fund 2
- Employees
- 3
- Headquarters
- London, United Kingdom
- Office address
- 20 NORTH AUDLEY STREET, London, W1K 6WE
- Business phone
- +44 203 940 6646
Stated criteria beside observed behaviour
1 observed deals
Stated by the firm
- Sectors
- life sciences
- Geography
- not stated or not yet read
- Revenue
- not stated or not yet read
- EBITDA
- not stated or not yet read
- Enterprise value
- not stated or not yet read
- Equity check
- not stated or not yet read
- Control
- not stated or not yet read
- Thesis
- 4BIO’s objective is to invest in, support, and grow early stage companies developing treatments in areas of high unmet medical need, with the ultimate goal of ensuring access to these potentially curative therapies for all patients.
Observed from deals on record
- roles
- unknown 1
- period
- to unknown, from unknown, undated holdings 1, dated observations 0
- window
- last unknown, first unknown
- control
- unknown 1
- companies
- 1
- geography
- investments
- 1
- seller kinds
- transactions
- 0
- cadence by year
- platform add on
- add ons 0, platforms 0, add ons per platform unknown
- sector known for
- 0
- disclosed value usd
- n 0
- sector distribution
- holding period years
- n 0
- repeat counterparties
- subsector distribution
1 companies on the graph (0 transactions); no dated observations
Funds
2 on record
| Fund | Vehicle | Vintage | Reported gross assets (Form ADV), not fund size | GAV by year | Form D sold | Lifecycle |
|---|---|---|---|---|---|---|
| 4••• V••••••• I•• L• ADV: P•••••• Equity Fund | buyout or unlabelled | 2023 first reported on Form ADV | $49.2M as of Oct 11, 2024 | no Form D | Early deployment | |
| 4••• V••••••• I• L• ADV: P•••••• Equity Fund | buyout or unlabelled | unknown | $110M as of Oct 11, 2024 | no Form D | Unknown |
Team
5 current, 0 former
Managing partner (3)
- A•••• H•••••• · Former CEO, Vifor Pharma; Global President Pharmaceuticals and Vaccines, GSK · start date unknown Investment organization websites (team, portfolio, strategy, criteria, news)
- A••••• K••••• · Managing Partner · since Apr 1, 2021 SEC Form ADV filing data 2011 to 2024 (Schedule D 7.B.(1) private funds, Schedules A/B, 1.I websites)
- D••••• A••••• K••••• · Managing Partner · since Apr 1, 2021 SEC Form ADV filing data 2011 to 2024 (Schedule D 7.B.(1) private funds, Schedules A/B, 1.I websites)
Platform (2)
- K••••• M••••• · Partner, General Counsel, Chief Compliance Officer · since Apr 1, 2021 SEC Form ADV filing data 2011 to 2024 (Schedule D 7.B.(1) private funds, Schedules A/B, 1.I websites)
- P••••••• F•••••• O•• · CHIEF OPERATING OFFICER · start date unknown Investment organization websites (team, portfolio, strategy, criteria, news)
Portfolio
1 relationships, 0 platforms, 0 add-ons
| Company | Role | Status | Invested | Held | Partner | Source |
|---|---|---|---|---|---|---|
| U• P•••••• C•••••• M••••• • L• | Role unknown | unknown | unknown | unknown | unknown | Fact Investment organization websites (team, portfolio, strategy, criteria, news) |
Transactions
0 on record
No transaction naming this firm has been collected yet. The deal tape is read from SEC filings and cited announcements.
Placement agents, lenders, advisers and co-investors
5 relationships
Placement agents (5)
- A••••••••• W•••••••• L•• 2 shared · recurring · last Jan 1, 2023
- B•••••••• P••••••• L••• 1 shared · one time · last Jan 1, 2021
- F•••• S••••••••• 1 shared · one time · last Jan 1, 2023
- E••••• C•••••• P•••••••• L•• 1 shared · one time · last Jan 1, 2023
- A••••• P•••••••• S•• 1 shared · one time · last Jan 1, 2021
LP commitments
0 disclosed
No LP commitment collected yet. An LP edge needs a public disclosure with a quote, such as a pension plan’s report or an announcement naming the LP.
Events
1 most recent
- Apr 29, 20214••• P••••••• L•• first filed Form ADV in the extract (IA)
Across the graphs
4••• P••••••• L•• is the same institution as 1 record in RIA and Wealth.
RIA and Wealth1
Which record it is in each graph, what it is called there, and what the two were joined on. The Data Factory holds all nine graphs and the identity layer between them.
Checking your plan…